Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 7 - Feb. 17, 2017
  • Audit: Lynda Chin’s abandoned $62 million IBM Watson collaboration didn’t follow standard procedures

    An audit of an abandoned mega-project run by IBM Watson and MD Anderson Cancer Center found that the Houston-based institution skirted the UT System’s procurement regulations as it spent $62.1 million on an ill-fated artificial intelligence system.

  • Is it research or run-of-the-mill IT?

    The UT System report on the Oncology Expert Advisor Project raises questions about classification of development of artificial intelligence systems.

    Are they research or are they IT systems?

  • Guest Editorial

    The AACI Network Care Initiative

    Many cancer center hospital systems are expanding their services across large geographic regions, while cancer care is consolidating around ever enlarging groups.

    Over the next two years, as I serve as president of the Association of American Cancer Institutes, I will be leading an initiative to better define these networks and to develop methods of improving the quality of cancer care administered across individual cancer center networks, with better integration of treatment services, especially those now unique to our centers, into the community.

  • In Brief

    • Salk scientist awarded $500K Swedish prize
    • Prostate Cancer Foundation awards $8.6 million to eight teams
    • U.S. Preventive Services Task Force appoints three new members
    • BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology
    • Perthera, Hope for Stomach Cancer to provide patient services
    • RPRD Diagnostics, Children’s Minnesota to advance clinical pharmacogenomics
    • Jeffery Kutok named chief scientific officer at Infinity
    • CVS Health earns CEO Cancer Gold Standard accreditation
  • Drugs and Targets

    • Amgen submits Supplemental Biologics License Application for Blincyto
    • Pan-Canadian Pharmaceutical Alliance, BMS reach agreement on Opdivo
    • Immunomedics enters into licensing agreement with Seattle Genetics for Sacituzumab Govitecan
  • Funding Opportunities

    PCRP announces research awards application guidelines

    The Department of Defense Prostate Cancer Research Program is pre-announcing the application process for its funding awards even though due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

Issue 6 - Feb. 10, 2017
  • MMRF contributes largest disease-specific cancer genome dataset to NCI’s Genomic Data Commons

    It took the Multiple Myeloma Research Foundation nearly a decade and over $40 million to create what the foundation describes as the largest disease-specific cancer genome dataset in existence.

    The first installment of the dataset is now posted on NCI’s Genomic Data Commons, which places the information in the public domain, making it available to researchers.

  • Conversation with The Cancer Letter

    Giusti: The $40 million multiple myeloma dataset will help predict risk and clinical response

    The world’s biggest genomic database on multiple myeloma is being integrated into NCI’s Genomic Data Commons.

    The data on the second most common blood cancer—with genomic information from about 1,400 patients—was compiled by the Multiple Myeloma Research Foundation through a genome mapping initiative and a $40 million network of clinical trials.

  • Steve Hahn takes over day to day operations at MD Anderson

    Steve Hahn, a radiation oncologist, was named deputy to the president and chief operating officer at MD Anderson Cancer Center.

  • GAO report: FDA underestimated actual cancer risk, clearing 25 versions of morcellators in over 20 years

    The Government Accountability Office Feb. 8 released an analysis of FDA’s failure to detect the health hazards of power morcellation, a once widely used procedure that has been shown to upstage uterine cancers.

  • In Brief

    • International teams win £100 million in Cancer Research UK competition 
    • Horning receives Duane Roth Memorial Award
    • Chang and Moore win Ehrlich-Darmstaedter Prize
    • ESMO to present new award at first annual Immuno-Oncology Congress
    • Jupiter Medical Center to use IBM Watson for Oncology technology
    • Fox Chase, Temple earn accreditation for BMT program
    • Cota, Hackensack integrate patient data into Epic EHR system
    • NCCN creates Quick Guide for patients with Waldenström’s Macroglobulinemia
  • Drugs & Targets

    • FDA approves Opdivo for urothelial carcinoma indication
    • GenomeDx, Astellas work to identify genomic drivers of Xtandi response
Issue 5 - Feb. 3, 2017
  • Soon-Shiong drops “MoonShot” trademark, but MD Anderson suit remains unresolved

    Overnight, cancer pharmaceuticals billionaire Patrick Soon-Shiong stopped using the trademark “MoonShot” to describe his health initiatives, opting instead to use the less grabby, but equally ambitious, name “cancer breakthroughs.”

  • Soon-Shiong’s journey from “Rocket Ship” to “MoonShot”—with lots of confusion

    The MD Anderson complaint against Patrick Soon-Shiong and his business entities, filed Nov. 30, 2016, in the U.S. District Court for the Southern District of Texas, argues that the controversial billionaire’s use of the moonshot trademark created confusion that affected both MD Anderson and the White House initiative headed by then Vice President Joe Biden.

  • Cancer groups: Trump travel ban could “retard scientific progress and adversely affect public health”

    President Donald Trump’s recent executive order that temporarily bars travel from seven Muslim-majority countries to the United States will negatively affect research institutions, public health, and innovation, cancer organizations say.

  • Obituary

    LeMaistre, a pioneer of cancer prevention and former MD Anderson president, dies at 92

     

    Charles Aubrey “Mickey” LeMaistre, a former president of MD Anderson Cancer and a pioneer of cancer prevention, died Jan. 27. He was 92.

  • In Brief

    • Keith Flaherty named editor-in-chief of AACR journal Clinical Cancer Research
    • Gottschalk named chair of bone marrow transplantation, cellular therapy at St. Jude
    • Guttridge named associate director for basic research at Ohio State
    • Heath named associate director for translational sciences at Karmanos
    • Howell joins Fox Chase Department of Radiation Oncology
    • NCCN establishes second policy and advocacy fellowship
  • Drugs & Targets

    • MD Anderson, Guardant form partnership to make liquid biopsy standard of care
    • Indivumed to provide tissue samples to Regeneron
    • Addario institute and Scancell form partnership focused on vaccine
    • Perthera enters collaboration with Novartis to identify patients for clinical trials
    • Benitec, Nant Capital initiate head and neck cancer programs
    • GenomeDx joins Astellas in genomic profiling collaboration
  • Funding Opportunities

    SU2C to fund Dream Teams focused on “cancer interception” in pancreas and lungs

    Stand Up To Cancer broke new ground today when the American Association for Cancer Research, its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception” of the pancreas and lungs.